Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Phase Separation of C9orf72 Dipeptide Repeats Perturbs Stress Granule Dynamics.

Molecular cell | 2017

Liquid-liquid phase separation (LLPS) of RNA-binding proteins plays an important role in the formation of multiple membrane-less organelles involved in RNA metabolism, including stress granules. Defects in stress granule homeostasis constitute a cornerstone of ALS/FTLD pathogenesis. Polar residues (tyrosine and glutamine) have been previously demonstrated to be critical for phase separation of ALS-linked stress granule proteins. We now identify an active role for arginine-rich domains in these phase separations. Moreover, arginine-rich dipeptide repeats (DPRs) derived from C9orf72 hexanucleotide repeat expansions similarly undergo LLPS and induce phase separation of a large set of proteins involved in RNA and stress granule metabolism. Expression of arginine-rich DPRs in cells induced spontaneous stress granule assembly that required both eIF2α phosphorylation and G3BP. Together with recent reports showing that DPRs affect nucleocytoplasmic transport, our results point to an important role for arginine-rich DPRs in the pathogenesis of C9orf72 ALS/FTLD.

Pubmed ID: 28306503 RIS Download

Associated grants

  • Agency: NIMH NIH HHS, United States
    Id: T32 MH020068
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM111700
  • Agency: NIGMS NIH HHS, United States
    Id: P20 GM104937
  • Agency: NINDS NIH HHS, United States
    Id: R35 NS097974
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM118530
  • Agency: European Research Council, International
    Id: 647458

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


UniProt (tool)

RRID:SCR_002380

Collection of data of protein sequence and functional information. Resource for protein sequence and annotation data. Consortium for preservation of the UniProt databases: UniProt Knowledgebase (UniProtKB), UniProt Reference Clusters (UniRef), and UniProt Archive (UniParc), UniProt Proteomes. Collaboration between European Bioinformatics Institute (EMBL-EBI), SIB Swiss Institute of Bioinformatics and Protein Information Resource. Swiss-Prot is a curated subset of UniProtKB.

View all literature mentions

Microsoft Excel (tool)

RRID:SCR_016137

Software application with data analysis tools and spreadsheet templates to track and visualize data. It is used to manage and process data.

View all literature mentions

ProteomeXchange (tool)

RRID:SCR_004055

A data repository for proteomic data sets. The ProteomeExchange consortium, as a whole, aims to provide a coordinated submission of MS proteomics data to the main existing proteomics repositories, as well as to encourage optimal data dissemination. ProteomeXchange provides access to a number of public databases, and users can access and submit data sets to the consortium's PRIDE database and PASSEL/PeptideAtlas.

View all literature mentions

Program to Reduce Incontinence by Diet and Exercise (tool)

RRID:SCR_009018

Randomized controlled trial being conducted at two clinical centers in the United States to learn more about the effects of weight loss on urinary incontinence. About 330 overweight women aged 30 or older will participate and will be followed for 18 months. Efficacy of weight reduction as a treatment for urinary incontinence will be examined at 6 months following the intensive weight control program, and the sustained impact of the intervention will be examined at 18 months. To increase the maintenance of weight reduction and facilitate evaluation of the enduring impact of weight loss on urinary incontinence, they propose to study a motivation-based weight maintenance program. At the end of the intensive weight control program, women randomized to the weight loss program will be randomized to either a 12-month skill-based maintenance intervention or to a motivation-based maintenance intervention. The maintenance interventions maximize the potential for sustained weight loss and will allow them to determine if long-term weight reduction will produce continued improvement in urinary incontinence.

View all literature mentions

MaxQuant (tool)

RRID:SCR_014485

A quantitative proteomics software package for analyzing large-scale mass-spectrometric data sets. It is a set of algorithms that include peak detection and scoring of peptides, mass calibration, database searches for protein identification, protein quantification, and provides summary statistics.

View all literature mentions

U2OS (tool)

RRID:CVCL_0042

Cell line U2OS is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

DDX6 antibody (antibody)

RRID:AB_941268

This polyclonal targets Human DDX6

View all literature mentions

TDP-43 (C-terminal) antibody (antibody)

RRID:AB_2200505

This polyclonal targets TDP-43 (C-terminal)

View all literature mentions

Ataxin-2 (antibody)

RRID:AB_398900

This monoclonal targets Ataxin-2

View all literature mentions

TIA-1 (C-20) (antibody)

RRID:AB_2201433

This polyclonal targets TIA-1 (C-20)

View all literature mentions

G3BP antibody (antibody)

RRID:AB_941699

This monoclonal targets G3BP antibody

View all literature mentions

YB1 antibody [EP2708Y] (antibody)

RRID:AB_2219276

This monoclonal targets Ybx1

View all literature mentions

HeLa (cell line)

RRID:CVCL_0030

Cell line HeLa is a Cancer cell line with a species of origin Homo sapiens

View all literature mentions

TIA-1 (C-20) (antibody)

RRID:AB_2201433

This polyclonal targets TIA-1 (C-20)

View all literature mentions

DDX6 antibody (antibody)

RRID:AB_941268

This polyclonal targets Human DDX6

View all literature mentions

G3BP antibody (antibody)

RRID:AB_941699

This monoclonal targets G3BP antibody

View all literature mentions

Ataxin-2 (antibody)

RRID:AB_398900

This monoclonal targets Ataxin-2

View all literature mentions

TDP-43 (C-terminal) antibody (antibody)

RRID:AB_2200505

This polyclonal targets TDP-43 (C-terminal)

View all literature mentions

DDX6 antibody (antibody)

RRID:AB_941268

This polyclonal targets Human DDX6

View all literature mentions

G3BP antibody (antibody)

RRID:AB_941699

This monoclonal targets G3BP antibody

View all literature mentions

YB1 antibody [EP2708Y] (antibody)

RRID:AB_2219276

This monoclonal targets Ybx1

View all literature mentions

TIA-1 (C-20) (antibody)

RRID:AB_2201433

This polyclonal targets TIA-1 (C-20)

View all literature mentions

Ataxin-2 (antibody)

RRID:AB_398900

This monoclonal targets Ataxin-2

View all literature mentions

TDP-43 (C-terminal) antibody (antibody)

RRID:AB_2200505

This polyclonal targets TDP-43 (C-terminal)

View all literature mentions

TIA-1 (C-20) (antibody)

RRID:AB_2201433

This polyclonal targets TIA-1 (C-20)

View all literature mentions

Ataxin-2 (antibody)

RRID:AB_398900

This monoclonal targets Ataxin-2

View all literature mentions

TDP-43 (C-terminal) antibody (antibody)

RRID:AB_2200505

This polyclonal targets TDP-43 (C-terminal)

View all literature mentions

DDX6 antibody (antibody)

RRID:AB_941268

This polyclonal targets Human DDX6

View all literature mentions

G3BP antibody (antibody)

RRID:AB_941699

This monoclonal targets G3BP antibody

View all literature mentions